Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

Forecasters anticipate exponential growth throughout the biotech industry over the coming decade, paving the way for a series of stock market opportunities for investors throughout this period. The ...

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major ...

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...

Fierce Biotech sat down with Pavel Raifeld, CEO of Innoviva, to explore the dynamic landscape of the biotech industry. Throughout the conversation, Raifeld offers a unique perspective on the most ...

F rom blockbuster drugs that garner media attention to smaller innovations that help millions maintain health, the biotech and pharmaceutical industries have an impact on everyone’s life. Meanwhile, ...

This column is from Trendlines, The Boston Globe’s business newsletter that covers the forces shaping the economy in Boston and beyond. If you’d like to receive it via email on Mondays and Thursdays, ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

Boston CEOs point to a rise in funding rounds and M&A deals in late 2025 as evidence that biotech companies are learning to ...